UNSPSC 51431505: Aliskiren fumarate

This classification denotes an antihypertensive agent with the molecular formula 2C30H53N3O6.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C8A0P8G029. European Medicines Agency schedules aliskiren fumarate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25393. The term aliskiren fumarate is a Japanese Accepted Name designation. Most nations, for tariff and trade purposes, schedule aliskiren fumarate under HS 29242995 and SITC 51479.

SMILES: CC(C)[C@@H](CC1CCC(C(C1)OCCCOC)OC)C[C@@H]([C@H](C[C@@H](C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N.CC(C)[C@@H](CC1CCC(C(C1)OCCCOC)OC)C[C@@H]([C@H](C[C@@H](C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N.C(=C/C(=O)O)\C(=O)O.

UNSPSC 51431505 Aliskiren fumarate is a Commodity code that captures state and local procurement of specific pharmaceutical products — in this case, a hypertension medication — but the recent opportunities block shows minimal direct activity under this narrow drug-specific code. Instead, the state and local market for branded and generic pharmaceuticals flows primarily through broader procurement vehicles: fire and rescue departments sourcing advanced life support medications in small quantities via sealed competitive bid; state health agencies conducting strategic market research into direct-to-manufacturer procurement models; and multistate cooperative purchasing alliances aggregating pharmaceutical demand across member jurisdictions to achieve volume discounts and standardized distribution through authorized wholesalers. The issuing bodies include municipal purchasing departments, state health and human services commissions, and cooperative purchasing organizations that serve multiple states. Aliskiren fumarate itself does not appear in the representative recent solicitations, which focus on epinephrine, labetalol, adenosine, and diltiazem for emergency medicine, or generic multi-source pharmaceuticals selected by therapeutic class rather than by individual active pharmaceutical ingredient.

Geographic activity is concentrated in Florida and Minnesota, with a multistate extension through Texas and Oregon. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) for advanced life support medications with a due date of April 8, 2026 and an estimated contract value of $40,000, sheltered for Small Local Business Enterprise participation at a 5 percent discount. The Minnesota Department of Administration, through the multistate MMCAP cooperative, posted an RFP (S1070000015802) due March 26, 2026 for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with contract effectiveness July 1, 2026. The Texas Health and Human Services Commission issued an RFI (HHS0017013) in early April 2026 to gather market intelligence on direct-to-manufacturer prescription programs, signaling potential future formal procurement but generating no immediate contract opportunity. Pursuit under this specific Commodity code is limited; broader pharmaceutical family and class codes likely capture most state and local drug procurement activity.